CEOs share lessons learned in biotech

Last week I attended Pennsylvania BIO's CEO Roundtable event, where Cephalon's Frank Baldino, Prism Pharmaceuticals' Warren Cooper and Fujirebio Diagnostics' Paul Touhey spoke to a room packed with the biotech industry's rank-and-file. They shared their thoughts on drug development, generic biologics, the current economic environment and managing biotech talent. Here's what they had to say. Article

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.